We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Protein Biomarker Linked to Delirium Duration

By LabMedica International staff writers
Posted on 06 Jan 2014
Print article
Image: The ETI-Max 3000 fully automated microtiter plate analyzer (Photo courtesy of DiaSorin).
Image: The ETI-Max 3000 fully automated microtiter plate analyzer (Photo courtesy of DiaSorin).
A protein biomarker appears to be linked to the duration of delirium and may have important implications for refining future delirium treatment in critically ill patients in intensive care units (ICU).

The calcium binding protein B (S100β) has previously been identified as a marker associated with delirium, and a study has now linked it to the duration of delirium in critically ill patients who suffer from the acute confusion and disorientation characteristic of delirium.

Scientists at the Indiana University School of Medicine (Indianapolis, IN, USA) performed a prospective observational cohort study on 63 delirious patients who were selected for the analysis, with two blood samples for S100β collected on days one and eight of enrollment.

S100β levels were measured in duplicate using a prevalidated commercially available assay kit (DiaSorin S.p.A.; Saluggia, Italy). This kit employs a two-site one-step enzyme linked immunosorbent assay and includes two positive controls of known concentration (one with less than 1.0 ng/mL and the other with more than 2.0 ng/mL of pure S100β antigen), as well as a negative control in every run. Normal values for S100β were established as below 0.10 ng/mL based on a previously published study of 200 healthy volunteers who showed a median plasma concentration of 0.052 ng/mL.

The investigators found that found that ICU patients with abnormally elevated levels of S100β either on day one or day eight, or both, had higher delirium duration compared to patients with normal S100β levels on both days. Adjusting for age, gender, race and other medical conditions, hospitalized patients with delirium have stays that are more than twice as long. They have a greater probability of being discharged to a long-term-care facility, and have a much higher probability of developing dementia than patients who do not experience delirium.

Babar Ali Khan, MD, who led the study, said, “Utilizing a simple blood test presents an easy and real opportunity to decrease the burden of the syndrome and thereby diminish progression to cognitive impairment in older adults. Since every day with delirium in the ICU is associated with a 10% increased likelihood of death, it's critical to diminish its duration and ultimately prevent it.” The study was published in the December 2013 issue of the International Journal of General Medicine.

Related Links:

Indiana University School of Medicine
DiaSorin 


Gold Member
Troponin T QC
Troponin T Quality Control
New
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Blood Gas Panel plus Electrolytes
i-STAT EG6+ Cartridge
New
Rheumatoid Arthritis Test
Finecare RF Rapid Quantitative Test

Print article

Channels

Molecular Diagnostics

view channel
Image: A coronal MRI section shows a high-intensity focused ultrasound lesion in the left thalamus of the brain (Photo courtesy of UT Southwestern Medical Center)

Newly Identified Stroke Biomarkers Pave Way for Blood Tests to Quickly Diagnose Brain Injuries

Each year, nearly 800,000 individuals in the U.S. experience a stroke, which occurs when blood flow to specific areas of the brain is insufficient, causing brain cells to die due to a lack of oxygen.... Read more

Immunology

view channel
Image: The discovery of biomarkers could improve endometrial cancer treatment (Photo courtesy of Mount Sinai)

Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer

Endometrial cancer, which develops in the lining of the uterus, is the most prevalent gynecologic cancer in the United States, affecting over 66,000 women annually. Projections indicate that in 2025, around... Read more

Pathology

view channel
Image: As tumor cells flow through these microfluidic chambers, they are subjected to increasing shear stress and sorted based on their adhesion strength (Photo courtesy of UC San Diego)

Microfluidic Device Assesses Stickiness of Tumor Cells to Predict Cancer Spread

Ductal carcinoma in situ (DCIS), a type of early-stage breast cancer, is often referred to as stage zero breast cancer. In many cases, it remains harmless and does not spread beyond the milk ducts where... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.